CTOs on the Move

Maze Therapeutics

www.mazetx.com

 
Maze Therapeutics is translating novel genetic insights into lifesaving medicines, through an approach that integrates human genetics and functional genomics.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million
  • www.mazetx.com
  • 131 Oyster Point Blvd Suite 200
    South San Francisco, CA USA 94080
  • Phone: N/A

Executives

Name Title Contact Details

Funding

Maze Therapeutics raised $191M on 02/28/2019
Maze Therapeutics raised $190M on 01/10/2022

Similar Companies

Oncorus

Oncorus, Inc. is a lean early-stage biotechnology company developing a next-generation immunotherapy platform to treat cancer. Oncorus was founded by well-known biotechnology entrepreneurs and is backed by MPM Capital. Oncorus is a leader in corporate philanthropy, and has taken a pledge to donate a portion of product sales to fund promising cancer research and to support cancer care in the developing world. We are located in Kendall Square, Cambridge, MA.

Plaxgen

Plaxgen is a Sunnyvale, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

AGC Biologics

AGC Biologics is a leading global Contract Development and Manufacturing Organization (CDMO), with a relentless commitment to deliver the highest standard of service to our clients and partners.

Folio Conversant

Folio Conversant is the premier provider of research services and biospecimen solutions. We offer an extensive array of quality biospecimens, particularly Human tissue and biofluids, supported by comprehensive laboratory and analytical services. Science does not stand still. Our goal is to become a key partner in supporting your team`s research and development in order to accelerate new diagnostic and therapeutic options for patients.

Silverback Therapeutics

Silverback Therapeutics is charting a new path for treating a range of severe diseases. We are developing therapies that act on fundamental biological pathways that underlie disease, but that modern medicine has not been able to fully harness — until now.